• Feel your memory isn’t what it used to be?

  • Feel your memory isn’t what it used to be?

  • Feel your memory isn’t what it used to be?

  • Feel your memory isn’t what it used to be?

  • Feel your memory isn’t what it used to be?

Feel your memory isn’t what it used to be? You’re not alone.

Worldwide, about 47 million people are living with dementia such as Alzheimer’s disease.1,2 It not only affects this global population, but also their families and caregivers.2 While there is currently no cure available, new drugs are being investigated in clinical trials.1

MissionAD is a global clinical research program currently enrolling participants to test an investigational drug for the early stages of Alzheimer’s disease, and is being conducted in 31 countries.3,4

About MissionAD

MissionAD is a global clinical research program testing a new investigational drug for the early stages of Alzheimer’s disease.3,4

Doctors are studying the safety of this drug to see if it may help people with early stages of Alzheimer’s disease in the future. The drug is not yet approved for use in the U.S. or any other country and is not available to the public.

People who qualify for this research study may receive:

  • The investigational drug at no cost
  • Study-related care from a local study doctor
  • Reimbursement for travel expenses for those who qualify and participate

Who can participate?

You may be eligible to participate if:

  • You are 50 to 85 years of age
  • You are experiencing noticeable changes in memory or thinking
  • You have a friend, spouse, or family member, who can accompany you to scheduled doctor visits
  • You test or have tested positive for the presence of amyloid in the brain

and

  • You have not been diagnosed with having had a stroke within the last year
  • You have not been diagnosed with epilepsy or another seizure disorder

Doctors will also check other requirements to confirm that you qualify for the study.

References

1. World Health Organization. Dementia Fact Sheet. May 2017. http://who.int/mediacentre/factsheets/fs362/en/. Accessed June 22, 2017.

2. Alzheimer’s Association. May 2014. http://alz.org/global/. Accessed June 22, 2017.

3. U.S. National Institutes of Health. A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease (MissionAD1). https://clinicaltrials.gov/ct2/show/NCT02956486. Accessed June 22, 2017.

4. U.S. National Institutes of Health. A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease (MissionAD2). https://clinicaltrials.gov/ct2/show/NCT03036280. Accessed June 22, 2017.

5. Vassar, R. BACE1 Inhibitor Drugs in Clinical Trials for Alzheimer’s Disease. Alzheimer's Research & Therapy:2014;6.89:1-14.

6. Alzheimer's Association. Mild Cognitive Impairment (MCI): Signs, Symptoms, & Diagnosis. May 2017. http://www.alz.org/dementia/mild-cognitive-impairment-mci.asp. Accessed June 22, 2017.

7. Alzheimer's Association. What Is Alzheimer's? May 2017. http://www.alz.org/alzheimers_disease_what_is_alzheimers.asp. Accessed June 22, 2017.

8. Alzheimer's Association. Stages of Alzheimer's & Symptoms. June 2017. http://www.alz.org/alzheimers_disease_stages_of_alzheimers.asp#mild. Accessed June 22, 2017.

9. Alzheimer's Association. Why Get Checked. June 2017. http://www.alz.org/alzheimers_disease_why_get_checked.asp. Accessed June 22, 2017.

10. Alzheimer's Association. Alzheimer’s and Dementia Testing for Earlier Diagnosis. June 2017. http://alz.org/research/science/earlier_alzheimers_diagnosis.asp. Accessed June 22, 2017.

11. National Institutes of Health. What Are Clinical Trials? May 2017. https://www.nhlbi.nih.gov/studies/clinicaltrials. Accessed June 22, 2017.